Arbutus drags Pfizer, BioNTech to court over patent infringements
HQ Team April 5, 2023: Arbutus Biopharma Corporation and Genevant Sciences filed a lawsuit in a US court seeking compensation for Pfizer and BioNTech’s unlicensed use.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team April 5, 2023: Arbutus Biopharma Corporation and Genevant Sciences filed a lawsuit in a US court seeking compensation for Pfizer and BioNTech’s unlicensed use.
HQ Team April 5, 2023: Johnson and Johnson, a US multinational making pharmaceuticals and medical devices, has offered to pay $8.9 billion to.
HQ Team April 4, 2023: About one in six people worldwide suffer from infertility, a disease that disables the male or female reproductive.
HQ Team April 3, 2023: BioNTech SE and Duality Biologics (Suzhou) have signed a $1.5 billion deal to develop and commercialise two cancer.
The CDC laboratory testing identified the presence of the outbreak strain in opened EzriCare bottles with different lot numbers collected from two states.
India has granted a complete customs duty exemption for the personal use of medicines to treat rare diseases, including Merc & Co’s Keytruda.
Aurobindo Pharma, an Indian maker of generic pharmaceuticals and active pharmaceutical ingredients, announced it signed a voluntary sub-licensing with a UN body for.
Indian billionaire Azim Premji's private equity and venture capitalist arm, Premji Invest, and Tube Investments, together will acquire Lotus Surgicals for INR 3.8.
US-based Emergent BioSolutions announced that FDA had approved its nasal spray Narcan as an over-the-counter emergency treatment for opioid overuse.
ndia’s Technology Development Board has signed a pact with Huwel Lifesciences for the validation and commercialisation of rapid real-time PCR reagents for storage.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com